138 related articles for article (PubMed ID: 23545663)
1. Consideration of dual anti-platelet therapy duration after drug-eluting stent implantation in a Japanese population: a five-year follow-up after sirolimus-eluting stent implantation.
Kotani J; Ikari Y; Kyo E; Nakamura M; Yokoi H;
Intern Med; 2013; 52(7):703-11. PubMed ID: 23545663
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial.
Kereiakes DJ; Yeh RW; Massaro JM; Driscoll-Shempp P; Cutlip DE; Steg PG; Gershlick AH; Darius H; Meredith IT; Ormiston J; Tanguay JF; Windecker S; Garratt KN; Kandzari DE; Lee DP; Simon DI; Iancu AC; Trebacz J; Mauri L;
JAMA; 2015 Mar; 313(11):1113-21. PubMed ID: 25781440
[TBL] [Abstract][Full Text] [Related]
3. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
Hermiller JB; Krucoff MW; Kereiakes DJ; Windecker S; Steg PG; Yeh RW; Cohen DJ; Cutlip DE; Massaro JM; Hsieh WH; Mauri L;
JACC Cardiovasc Interv; 2016 Jan; 9(2):138-47. PubMed ID: 26793956
[TBL] [Abstract][Full Text] [Related]
4. Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
Tada T; Natsuaki M; Morimoto T; Furukawa Y; Nakagawa Y; Byrne RA; Kastrati A; Kadota K; Iwabuchi M; Shizuta S; Tazaki J; Shiomi H; Abe M; Ehara N; Mizoguchi T; Mitsuoka H; Inada T; Araki M; Kaburagi S; Taniguchi R; Eizawa H; Nakano A; Suwa S; Takizawa A; Nohara R; Fujiwara H; Mitsudo K; Nobuyoshi M; Kita T; Kimura T;
Circ Cardiovasc Interv; 2012 Jun; 5(3):381-91. PubMed ID: 22619260
[TBL] [Abstract][Full Text] [Related]
5. Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy.
Lee BK; Kim JS; Lee OH; Min PK; Yoon YW; Hong BK; Shin DH; Kang TS; Kim BO; Cho DK; Jeon DW; Woo SI; Choi S; Kim YH; Kang WC; Kim S; Kim BK; Hong MK; Jang Y; Kwon HM
EuroIntervention; 2018 Mar; 13(16):1923-1930. PubMed ID: 29104179
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
Lee SY; Hong MK; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Kim HS; Valgimigli M; Palmerini T; Stone GW
Clin Res Cardiol; 2017 Mar; 106(3):165-173. PubMed ID: 27631821
[TBL] [Abstract][Full Text] [Related]
7. One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients needing short dual antiplatelet therapy. Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry).
Godino C; Beneduce A; Ferrante G; Ielasi A; Pivato CA; Chiarito M; Cappelletti A; Perfetti G; Magni V; Prati E; Falcone S; Pierri A; De Martini S; Montorfano M; Parisi R; Rutigliano D; Locuratolo N; Anzuini A; Tespili M; Margonato A; Benassi A; Briguori C; Fabbiocchi F; Reimers B; Bartorelli A; Colombo A
Int J Cardiol; 2019 Sep; 290():52-58. PubMed ID: 30917900
[TBL] [Abstract][Full Text] [Related]
8. Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial.
Han Y; Xu B; Xu K; Guan C; Jing Q; Zheng Q; Li X; Zhao X; Wang H; Zhao X; Li X; Yu P; Zang H; Wang Z; Cao X; Zhang J; Pang W; Li J; Yang Y; Dangas GD
Circ Cardiovasc Interv; 2016 Feb; 9(2):e003145. PubMed ID: 26858080
[TBL] [Abstract][Full Text] [Related]
9. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
[TBL] [Abstract][Full Text] [Related]
10. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
Gilard M; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berland J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Endresen K; Benamer H; Kiss RG; Ungi I; Boschat J; Morice MC
J Am Coll Cardiol; 2015 Mar; 65(8):777-786. PubMed ID: 25461690
[TBL] [Abstract][Full Text] [Related]
11. Dual antiplatelet therapy over 6 months increases the risk of bleeding after biodegradable polymer-coated sirolimus eluting stents implantation: insights from the CREATE study.
Zhang L; Li Y; Jing QM; Wang XZ; Ma YY; Wang G; Xu B; Gao RL; Han YL;
J Interv Cardiol; 2014 Apr; 27(2):119-26. PubMed ID: 24617336
[TBL] [Abstract][Full Text] [Related]
12. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial.
Collet JP; Silvain J; Barthélémy O; Rangé G; Cayla G; Van Belle E; Cuisset T; Elhadad S; Schiele F; Lhoest N; Ohlmann P; Carrié D; Rousseau H; Aubry P; Monségu J; Sabouret P; O'Connor SA; Abtan J; Kerneis M; Saint-Etienne C; Beygui F; Vicaut E; Montalescot G;
Lancet; 2014 Nov; 384(9954):1577-85. PubMed ID: 25037988
[TBL] [Abstract][Full Text] [Related]
13. Prospective multicentre open-label randomised controlled trial of 3-month versus 12-month dual antiplatelet therapy after implantation of the new generation biodegradable polymer sirolimus TARGET-eluting coronary stent: protocol of the TARGET DAPT trial.
Yang H; Zhang F; Yang J; Zheng M; Cao R; Dai Y; Li C; Yao K; Qian J; Ge J;
BMJ Open; 2019 Dec; 9(12):e033774. PubMed ID: 31852711
[TBL] [Abstract][Full Text] [Related]
14. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
[TBL] [Abstract][Full Text] [Related]
15. Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial.
Yun KH; Lee SY; Cho BR; Jang WJ; Song YB; Oh JH; Chun WJ; Park YH; Im ES; Jeong JO; Oh SK; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; Hahn JY;
J Am Heart Assoc; 2021 Jan; 10(1):e018366. PubMed ID: 33345567
[TBL] [Abstract][Full Text] [Related]
16. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
Valgimigli M; Patialiakas A; Thury A; McFadden E; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Airoldi F; Ferlini M; Liistro F; Dellavalle A; Vranckx P; Briguori C;
J Am Coll Cardiol; 2015 Mar; 65(8):805-815. PubMed ID: 25720624
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of 6-month versus 12-month dual antiplatelet therapy in patients after implantation of multiple biodegradable polymer-coated sirolimus-eluting coronary stents: Insight from the I-LOVE-IT 2 trial.
Qi J; Li Y; Li J; Jing Q; Xu K; Gao C; Ma L; Zhang Z; Xu B; Han Y
Catheter Cardiovasc Interv; 2017 Mar; 89(S1):555-564. PubMed ID: 28318138
[TBL] [Abstract][Full Text] [Related]
18. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
[TBL] [Abstract][Full Text] [Related]
19. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.
Yeh RW; Kereiakes DJ; Steg PG; Cutlip DE; Croce KJ; Massaro JM; Mauri L;
J Am Coll Cardiol; 2017 Oct; 70(18):2213-2223. PubMed ID: 29073947
[TBL] [Abstract][Full Text] [Related]
20. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
